CN114555053B - 治疗乳腺癌的方法 - Google Patents
治疗乳腺癌的方法Info
- Publication number
- CN114555053B CN114555053B CN202080071066.3A CN202080071066A CN114555053B CN 114555053 B CN114555053 B CN 114555053B CN 202080071066 A CN202080071066 A CN 202080071066A CN 114555053 B CN114555053 B CN 114555053B
- Authority
- CN
- China
- Prior art keywords
- dapam
- shu jing
- breast cancer
- mice
- tumor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- C07K16/245—IL-1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962914833P | 2019-10-14 | 2019-10-14 | |
| US62/914,833 | 2019-10-14 | ||
| PCT/US2020/055219 WO2021076444A1 (en) | 2019-10-14 | 2020-10-12 | Methods for treating breast cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN114555053A CN114555053A (zh) | 2022-05-27 |
| CN114555053B true CN114555053B (zh) | 2025-09-30 |
Family
ID=75538857
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202080071066.3A Active CN114555053B (zh) | 2019-10-14 | 2020-10-12 | 治疗乳腺癌的方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US12582628B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4045009A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2022551672A (cg-RX-API-DMAC7.html) |
| CN (1) | CN114555053B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2020366300B2 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021076444A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2025501657A (ja) * | 2022-01-10 | 2025-01-22 | オラテック セラピューティクス, インコーポレイティド | 膵臓がんを治療するための方法 |
| EP4487122A4 (en) * | 2022-03-02 | 2026-03-11 | Olatec Therapeutics Inc | TREATMENT METHODS FOR PATIENTS WITH SOLID CANCER AND CLONAL HEMATOPOIESIS OF UNDETERMINED POTENTIAL |
| WO2026035767A1 (en) * | 2024-08-06 | 2026-02-12 | Olatec Therapeutics, Inc. | Methods for treating melanoma metastasis to liver and lungs |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019182981A1 (en) * | 2018-03-21 | 2019-09-26 | Olatec Therapeutics Llc | Methods for treating melanoma |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2013006708A (es) | 2010-12-15 | 2013-09-13 | Olatec Ind Llc | Composicion de 3-metanosulfonilpropionitrilo para el tratamiento de la inflamacion y el dolor. |
| CN104768553A (zh) * | 2012-11-02 | 2015-07-08 | 默克专利股份公司 | 用于治疗肝细胞癌(hcc)的6-氧代-1,6-二氢-哒嗪衍生物 |
| UA122479C2 (uk) * | 2014-01-24 | 2020-11-25 | Дана-Фарбер Кенсер Інстітьют, Інк. | Виділена молекула антитіла, яка зв’язується з людським білком програмованої смерті-1 (pd-1) |
| ES2970485T3 (es) * | 2017-01-06 | 2024-05-29 | Olatec Therapeutics Llc | Composición farmacéutica para su uso en el tratamiento de enfermedades cardiovasculares |
| EP3589370A4 (en) * | 2017-01-06 | 2020-11-18 | Olatec Therapeutics LLC | MULTIPLE SCLEROSIS TREATMENT METHOD |
| AU2018313164A1 (en) * | 2017-08-11 | 2020-03-19 | Olatec Therapeutics Llc | Method for treating Schnitzler's syndrome |
| WO2019152627A1 (en) * | 2018-01-31 | 2019-08-08 | Olatec Therapeutics Llc | Method for preventing or treating alzheimer's disease |
-
2020
- 2020-10-12 EP EP20877745.8A patent/EP4045009A4/en active Pending
- 2020-10-12 WO PCT/US2020/055219 patent/WO2021076444A1/en not_active Ceased
- 2020-10-12 JP JP2022522322A patent/JP2022551672A/ja active Pending
- 2020-10-12 AU AU2020366300A patent/AU2020366300B2/en active Active
- 2020-10-12 CN CN202080071066.3A patent/CN114555053B/zh active Active
-
2022
- 2022-04-13 US US17/659,121 patent/US12582628B2/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019182981A1 (en) * | 2018-03-21 | 2019-09-26 | Olatec Therapeutics Llc | Methods for treating melanoma |
Non-Patent Citations (1)
| Title |
|---|
| Blocking IL-1β reverses the immunosuppression inmouse breast cancer and synergizes with anti–PD-1for tumor abrogation;Irena Kaplanov;《Proc. Natl. Acad. Sci. U.S.A.》;20190122;第116卷(第4期);第1361-1369页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2020366300B2 (en) | 2026-05-21 |
| EP4045009A4 (en) | 2023-11-01 |
| CN114555053A (zh) | 2022-05-27 |
| JP2022551672A (ja) | 2022-12-12 |
| EP4045009A1 (en) | 2022-08-24 |
| WO2021076444A1 (en) | 2021-04-22 |
| US20220249425A1 (en) | 2022-08-11 |
| AU2020366300A1 (en) | 2022-06-02 |
| US12582628B2 (en) | 2026-03-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12582628B2 (en) | Methods for treating breast cancer | |
| EP2684569A1 (en) | A composition for treatment of advanced prostate cancer | |
| EP2471548A1 (de) | siRNA gegen Cbl-b und optional IL2 und IL12 zur Verwendung in der Behandlung von Krebs | |
| US11857529B2 (en) | Methods for treating melanoma | |
| JP2848922B2 (ja) | 胸膜の原発癌を治療する意図の薬剤組成物を製造するためのヒトインターロイキン2の活性を有するポリペプチドの使用 | |
| CN113905764A (zh) | 用于治疗癌症的前体半胱天冬酶-3活化作用和免疫疗法 | |
| Brown et al. | Interferons and bladder cancer | |
| US20240417812A1 (en) | Methods for treating solid cancer patients with clonal hematopoiesis of indeterminate potential | |
| US20240358669A1 (en) | Methods for treating pancreatic cancer | |
| EP4536665A1 (en) | Novel ras inhibitors | |
| WO2023242107A1 (en) | Novel ras inhibitors | |
| WO2023242106A1 (en) | Novel ras inhibitors | |
| AU2023290433A1 (en) | Novel ras inhibitors | |
| WO2023242097A1 (en) | Mitoxanthrone derivatives as ras inhibitors | |
| EP4536635A1 (en) | Novel ras inhibitors | |
| EP4536203A1 (en) | Diaminoacridine derivatives as inhibitors of ras | |
| EP4654961A1 (en) | Novel mixtures as ras inhibitors for use in the treatment of proliferative and genetic diseases | |
| Eisenhrand | I Drug Development in Oncology | |
| HK1193755A (en) | A composition for treatment of advanced prostate cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB02 | Change of applicant information | ||
| CB02 | Change of applicant information |
Country or region after: U.S.A. Address after: USA New York Applicant after: Oratec Treatment Co. Address before: USA New York Applicant before: OLATEC INDUSTRIES LLC Country or region before: U.S.A. |
|
| GR01 | Patent grant | ||
| GR01 | Patent grant |